Cargando…

Synergy between health technology assessments and clinical guidelines for multiple sclerosis

Decision‐making for reimbursement and clinical guidelines (CGs) serves different purposes although the decision‐criteria and required evidence largely overlap. This study aimed to assess similarities and discrepancies between health technology assessment (HTA) reports as compared to CGs for multiple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hogervorst, Milou A., Vreman, Rick A., Zawada, Anna, Zielińska, Magdalena, Dawoud, Dalia M., de Jong, Brigit A., Mantel‐Teeuwisse, Aukje K., Goettsch, Wim G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175979/ https://www.ncbi.nlm.nih.gov/pubmed/36855929 http://dx.doi.org/10.1111/cts.13492

Ejemplares similares

Real World Data in Health Technology Assessment of Complex Health Technologies
por: Hogervorst, Milou A., et al.
Publicado: (2022)

Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
por: Hogervorst, Milou A, et al.
Publicado: (2023)

When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs
por: Callenbach, Marcelien H. E., et al.
Publicado: (2022)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
por: Vreman, Rick A., et al.
Publicado: (2020)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study
por: Ogar, Comfort K., et al.
Publicado: (2023)

Delayed payment schemes in Central-Eastern Europe and Middle-East
por: Ádám, Ildikó, et al.
Publicado: (2022)

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making of oncology medicines
por: Kalf, Rachel R. J., et al.
Publicado: (2021)

Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa
por: Narsai, Kirti, et al.
Publicado: (2012)

Compliance of Disease Awareness Campaigns in Printed Dutch Media with National and International Regulatory Guidelines
por: Leonardo Alves, Teresa, et al.
Publicado: (2014)

Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
por: Moerlie, Ashwin R., et al.
Publicado: (2020)

Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study
por: Sagwa, Evans L, et al.
Publicado: (2014)

Systematic reviews of ten pharmaceutical pricing policies – a research protocol
por: Tordrup, David, et al.
Publicado: (2020)

Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda
por: Kibira, Denis, et al.
Publicado: (2017)

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study
por: Ankrah, Daniel N. A., et al.
Publicado: (2017)

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
por: Joosse, Iris R, et al.
Publicado: (2023)

Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals’ preferences
por: Dankers, Marloes, et al.
Publicado: (2021)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Characteristics of drugs safety signals that predict safety related product information update
por: Insani, Widya N., et al.
Publicado: (2018)

The double opioid crisis: A call for balance
por: Vranken, Marjolein J.M., et al.
Publicado: (2019)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
por: Vreman, Rick A., et al.
Publicado: (2019)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Facilitators and barriers to antiretroviral therapy adherence among adolescents in Ghana
por: Ankrah, Daniel NA, et al.
Publicado: (2016)

Missing data on accessibility of children’s medicines
por: Joosse, Iris R, et al.
Publicado: (2022)

Essential Medicines Are More Available than Other Medicines around the Globe
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
por: Dankers, Marloes, et al.
Publicado: (2022)

Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements
por: Dankers, Marloes, et al.
Publicado: (2023)

Evidence on the effectiveness of policies promoting price transparency - A systematic review
por: Joosse, Iris R., et al.
Publicado: (2023)

National medicines policies – a review of the evolution and development processes
por: Hoebert, Joëlle M, et al.
Publicado: (2013)

Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia
por: Sagwa, Evans L, et al.
Publicado: (2016)

The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study
por: Jacobs, Tom G., et al.
Publicado: (2018)

Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review
por: Jacobs, Tom G., et al.
Publicado: (2019)

Access to sexual and reproductive health commodities in East and Southern Africa: a cross-country comparison of availability, affordability and stock-outs in Kenya, Tanzania, Uganda and Zambia
por: Ooms, Gaby I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_44nqsbjq1d7qs5k9pm3aslmcma